|
Adenocarcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
GEC C1galt1-/- mice exhibited spontaneous gastritis that progressed to adenocarcinoma with ∼80% penetrance by 1 yr. GEC C1galt1-/- gastric epithelium exhibited defective expression of a major mucus forming O-glycoprotein Muc5AC relative to WT controls, which was associated with impaired gastric acid homeostasis.
|
31645367 |
2020 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
More than 80% of PDAC aberrantly expresses the sialyl Tn (STn) antigen due to the loss of function of the core 1<i>β</i>3-Gal-T-specific molecular chaperone, a specific chaperone for the activity of core 1 <i>β</i>3-galactosyltransferase or C1GalT.
|
30683666 |
2019 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
To knock out T-synthase, we used CRISPR-Cas9 technology to target C1GALT1, the gene encoding T-synthase, in a CRC cell line (HCT116).
|
30035127 |
2018 |
|
Esophageal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
C1GalT1 knockdown increased the radiosensitivity of esophageal cancer cells, and attenuated irradiation-enhanced migration and invasion.
|
30087707 |
2018 |
|
Esophageal carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
C1GalT1 knockdown increased the radiosensitivity of esophageal cancer cells, and attenuated irradiation-enhanced migration and invasion.
|
30087707 |
2018 |
|
Malignant Head and Neck Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer.
|
29930379 |
2018 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our work collectively indicates that C1GALT1 is associated with O-glycosylated MUC1 in ESCC, not only suggesting a diagnostic significance of C1GALT1 and MUC1 O-glycosylation in ESCC, but also opening novel insights into targeting C1GALT1 and MUC1 O-glycosylation to suppress ESCC cells metastasis in patients.
|
30076562 |
2018 |
|
Malignant neoplasm of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using transcriptomic analysis of prostate cancer data sets, histopathologic examination of clinical specimens, and in vivo experiments of xenograft models, we reveal in this study a coordinated increase in glycan-binding protein, galectin-4, specific glycosyltransferases of core 1 synthase, glycoprotein- N-acetylgalactosamine 3-β-galactosyltransferase 1 (C1GALT1) and ST3 beta-galactoside α-2,3-sialyltransferase 1 (ST3GAL1), and resulting mucin-type O-glycans during the progression of CRPC.
|
29906246 |
2018 |
|
Malignant neoplasm of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
C1GalT1 knockdown increased the radiosensitivity of esophageal cancer cells, and attenuated irradiation-enhanced migration and invasion.
|
30087707 |
2018 |
|
Prostate carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using transcriptomic analysis of prostate cancer data sets, histopathologic examination of clinical specimens, and in vivo experiments of xenograft models, we reveal in this study a coordinated increase in glycan-binding protein, galectin-4, specific glycosyltransferases of core 1 synthase, glycoprotein- N-acetylgalactosamine 3-β-galactosyltransferase 1 (C1GALT1) and ST3 beta-galactoside α-2,3-sialyltransferase 1 (ST3GAL1), and resulting mucin-type O-glycans during the progression of CRPC.
|
29906246 |
2018 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
More importantly, co-expression of MUC1 Oglycosylation and C1GALT1 presented positive correlations with both lymph node metastasis and survival time of ESCC patients.
|
30076562 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
C1GALT1 overexpression enhances HNSCC cell viability, migration, and invasion, which can be reversed by erlotinib.
|
29930379 |
2018 |
|
Hormone refractory prostate cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using transcriptomic analysis of prostate cancer data sets, histopathologic examination of clinical specimens, and in vivo experiments of xenograft models, we reveal in this study a coordinated increase in glycan-binding protein, galectin-4, specific glycosyltransferases of core 1 synthase, glycoprotein- N-acetylgalactosamine 3-β-galactosyltransferase 1 (C1GALT1) and ST3 beta-galactoside α-2,3-sialyltransferase 1 (ST3GAL1), and resulting mucin-type O-glycans during the progression of CRPC.
|
29906246 |
2018 |
|
Head and Neck Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer.
|
29930379 |
2018 |
|
ovarian neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study aimed to explore the role of C1GALT1 in ovarian cancer.
|
28498248 |
2017 |
|
Malignant neoplasm of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study aimed to explore the role of C1GALT1 in ovarian cancer.
|
28498248 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study aimed to explore the role of C1GALT1 in ovarian cancer.
|
28498248 |
2017 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings suggest that C1GALT1 enhances breast cancer malignant progression through promoting MUC1-C/β-catenin signaling pathway.
|
25762620 |
2015 |
|
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
For comparison, mRNA expression of glycosylation enzymes involved in the synthesis of HPA and PNA binding glycostructures (GALNT family members and C1GALT1) was analyzed in microarray data of 194 carcinomas.
|
25975956 |
2015 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings suggest that C1GALT1 enhances breast cancer malignant progression through promoting MUC1-C/β-catenin signaling pathway.
|
25762620 |
2015 |
|
Malignant tumor of colon
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
It was found that siRNA suppression of C1GalT markedly reduced the expression of Galβ1,3GalNAcα- (Core 1) and in the meantime increased the expressions of sialyl-GalNAcα- (sialyl-Tn), GalNAcα- (Tn) and GlcNAcβ1,3GalNAcα- (Core 3)-associated glycans in human colon cancer HT29 and SW620 cells.
|
23536887 |
2013 |
|
Henoch-Schoenlein Purpura
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study is to investigate the association between polymorphisms in C1GALT1 gene and the risk of HSP in a Chinese population.
|
23624553 |
2013 |
|
Colon Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
It was found that siRNA suppression of C1GalT markedly reduced the expression of Galβ1,3GalNAcα- (Core 1) and in the meantime increased the expressions of sialyl-GalNAcα- (sialyl-Tn), GalNAcα- (Tn) and GlcNAcβ1,3GalNAcα- (Core 3)-associated glycans in human colon cancer HT29 and SW620 cells.
|
23536887 |
2013 |
|
Glomerulonephritis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We did not find a significant difference in the prevalence of the MCP-1 -2518 A > G and C1GalT1 1365 A > G polymorphisms in patients with primary GN and healthy individuals.
|
22203484 |
2012 |
|
Henoch-Schonlein purpura nephritis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our study suggested that the 1365 G/A polymorphism of the C1GALT1 gene may contribute to HSPN development.
|
22544166 |
2012 |